Seeking Alpha·Sep 15, 2026
Alector, Inc. (ALEC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptAlector, Inc. (ALEC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alector faces a precarious financial outlook as its immuno-neurology pipeline development continues to outpace revenue generation, leading to a rapid erosion of shareholder equity from $134.2 million in 2023Q4 to $10.4 million in 2026Q1. The company's reliance...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.21+8.1% vs -$0.23 | $3M+93.8% vs $2M |
Q2 2026 May 7, 2026 | -$0.21+40.0% vs -$0.35 | $1M-89.2% vs $10M |
Q1 2026 Feb 25, 2026 | -$0.34+12.8% vs -$0.39 | $6M+218.6% vs $2M |
Q4 2025 Nov 6, 2025 | -$0.34+19.0% vs -$0.42 | $3M+82.8% vs $2M |
Alector, Inc. (ALEC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alector, Inc. (ALEC) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Prepared Remarks Transcript
Alector (NASDAQ: ALEC - Get Free Report) and Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation. Profitability This table compares Alector and Sarepta Therapeutics' net
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026 (New York, New York) Thursday, September 10, 2026, at 2:10 p.m.
Benchmark ALEC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Alector, Inc. (ALEC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.02 | $224.27M | -1.45 | -79.07% | -679.16% | -181.56% | — | |
| $8.68 | $454.43M | -1.92 | -92.84% | -80.67% | -14.98% | — | |
| $25.43 | $4.35B | 11.10 | 11.87% | 33.42% | 32.39% | — | |
| $0.94 | $45.26M | -1.80 | — | — | -95.77% | — | |
| $2.35 | $217.78M | -4.35 | — | — | -30.07% | — | |
| $2.00 | $53.17M | -1.08 | 257.14% | — | -82.87% | — |
Alector, Inc. (ALEC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Alector, Inc. (ALEC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 8, 2026·SEC
Jun 17, 2026·SEC
Get notified when ALEC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Alector, Inc. (ALEC) stock FAQ — growth, dividends, profitability & financials explained
Alector, Inc. (ALEC) reported $13.9M in revenue for fiscal year 2025. This represents a 3232% increase from $0.4M in 2016.
Alector, Inc. (ALEC) saw revenue decline by 79.1% over the past year.
Alector, Inc. (ALEC) reported a net loss of $117.9M for fiscal year 2025.
Alector, Inc. (ALEC) has a return on equity (ROE) of -181.6%. Negative ROE indicates the company is unprofitable.
Alector, Inc. (ALEC) had negative free cash flow of $158.4M in fiscal year 2025, likely due to heavy capital investments.
